PD Dr. Hanna Hübner

Department of Obstetrics and Gynaecology Medizinische Fakultät Professur für Experimentelle Tumorpathologie

Procoagulant extracellular vesicles alter trophoblast differentiation in mice by a thrombo-inflammatory mechanism (2021) Markmeyer P, Lochmann F, Singh KK, Gupta A, Younis R, Shahzad K, Biemann R, et al. Journal article No evidence of the unfolded protein response in the placenta of two rodent models of preeclampsia and intrauterine growth restriction (2021) Denkl B, Cordasic N, Hübner H, Menendez-Castro C, Schmidt M, Mocker A, Wölfle J, et al. Journal article Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis (2021) Fasching P, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, et al. Journal article NGS zur Selektion innovativer Therapien – Was bringt das? (2021) Schulmeyer C, Bader S, Hübner H, Rübner M, Fasching P Journal article, Review article Placental thromboinflammation impairs embryonic survival by reducing placental thrombomodulin expression (2021) Kohli S, Singh KK, Gupta A, Markmeyer P, Lochmann F, Gupta D, Rana R, et al. Journal article Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis (2021) Hübner H, Lubrich H, Blum S, Antoniadis S, Lermann J, Ekici AB, Fasching P, et al. Journal article Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany (2020) Hübner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Journal article HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment (2020) Würfel F, Hübner H, Häberle L, Gaß P, Hein A, Jud S, Hack C, et al. Journal article Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article